Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about KYTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Mivocabtagene Autoleucel (KYV-101) | Myasthenia Gravis | Phase 2/3 · NCT06193889 | Recruiting |
| Anti-CD20 mAB | Multiple Sclerosis, Primary Progressive | Phase 2 · NCT06384976 | Active not recruiting |
| Chemotherapy: cyclophosphamide (CYC) | Progressive Multiple Sclerosis | Phase 1 · NCT06451159 | Active not recruiting |
| Chemotherapy: fludarabine (FLU) | Progressive Multiple Sclerosis | Phase 1 · NCT06451159 | Active not recruiting |
| Fludarabine | Idiopathic Inflammatory Myopathies | Phase 1 · NCT06152172 | Active not recruiting |
| Chimeric Antigen Receptor T-cells | Progressive Multiple Sclerosis | Phase 1 · NCT06451159 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not KYTX's own candidates): Cyclophosphamide, Rituximab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
KYTX holds $170.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $37.8M/quarter from operations, an estimated runway of 13.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 57 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KYTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Dr. Beth C. Seidenberg ("Seidenberg") | 5%+ holder (13G) | 4,657,257 | 7.37% | 2025-12-31 |
| Fred E Cohen Director · +85,933 options |
Insider | 4,545,651 | 7.19% | 2026-05-27 |
| GordonMD Global Investments LP | Institution (13G, 5%+) | 4,521,318 | 7.15% | 2026-09-30 |
| Gilead Sciences Inc | Institution (13F) | 4,126,119 | 6.53% | 2026-09-30 |
| Westlake BioPartners Opportunity Fund I, 10% owner |
Insider | 3,787,940 | 5.99% | 2025-12-18 |
| Orin Hirschman | Institution (13G, 5%+) | 3,650,000 | 5.77% | 2026-09-30 |
| AIGH Capital Management LLC | Institution (13F) | 3,650,000 | 5.77% | 2026-09-30 |
| Michael P. Rubin | 5%+ holder (13G) | 3,466,826 | 5.48% | 2025-12-31 |
| BlackRock, Inc. | Institution (13G, 5%+) | 3,103,757 | 4.91% | 2026-06-30 |
| Vanguard Capital Management LLC | Institution (13F) | 2,011,138 | 3.18% | 2026-09-30 |
| Bain Capital Life Sciences Investors, LL | Institution (13F) | 1,312,000 | 2.08% | 2026-09-30 |
| Price (T.Rowe) Associates Inc | Institution (13F) | 1,207,564 | 1.91% | 2026-09-30 |
Share count 63,221,970 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-05-27 filed 2026-05-29 |
Aktar Mert |
Award (A) | 5,093 | – | 21,727 |
| 2026-05-27 filed 2026-05-29 |
Shaw Christi |
Tax withholding (F) | 4,194 | $8.59 | 66,741 |
| 2026-05-27 filed 2026-05-29 |
Cohen Fred E |
Option award (A) | 20,582 | – | – |
| 2026-05-27 filed 2026-05-29 |
Cohen Fred E |
Award (A) | 5,093 | – | 21,727 |
| 2026-05-27 filed 2026-05-29 |
CLARK IAN T |
Option award (A) | 20,582 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KYTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →